These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10772373)

  • 1. Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters.
    Pickerill KE; Paladino JA; Schentag JJ
    Pharmacotherapy; 2000 Apr; 20(4):417-28. PubMed ID: 10772373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models.
    Schentag JJ; Meagher AK; Forrest A
    Ann Pharmacother; 2003 Sep; 37(9):1287-98. PubMed ID: 12921513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parameters.
    Paladino JA; Callen WA
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():43-7. PubMed ID: 12702703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
    Aliabadi FS; Lees P
    J Vet Pharmacol Ther; 2002 Jun; 25(3):161-74. PubMed ID: 12081611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of fluoroquinolones.
    Lode H; Borner K; Koeppe P
    Clin Infect Dis; 1998 Jul; 27(1):33-9. PubMed ID: 9675446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients.
    Schentag JJ
    Am J Health Syst Pharm; 1999 Nov; 56(22 Suppl 3):S21-4. PubMed ID: 10580737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of fluoroquinolones.
    Turnidge J
    Drugs; 1999; 58 Suppl 2():29-36. PubMed ID: 10553702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
    MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
    J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
    Highet VS; Forrest A; Ballow CH; Schentag JJ
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of marbofloxacin in horses.
    Bousquet-Melou A; Bernard S; Schneider M; Toutain PL
    Equine Vet J; 2002 Jul; 34(4):366-72. PubMed ID: 12117108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones.
    Dudley MN
    Am J Med; 1991 Dec; 91(6A):45S-50S. PubMed ID: 1767806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing efficacy and reducing the emergence of resistance.
    Wise R
    J Antimicrob Chemother; 2003 May; 51 Suppl 1():37-42. PubMed ID: 12702702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.
    Schentag JJ; Meagher AK; Forrest A
    Ann Pharmacother; 2003 Oct; 37(10):1478-88. PubMed ID: 14519053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis.
    Andes DR; Craig WA
    Clin Infect Dis; 1998 Jul; 27(1):47-50. PubMed ID: 9675448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do we really know about antibiotic pharmacodynamics?
    Gunderson BW; Ross GH; Ibrahim KH; Rotschafer JC
    Pharmacotherapy; 2001 Nov; 21(11 Pt 2):302S-318S. PubMed ID: 11714222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.